Cargando…
MEK1/2 as a Therapeutic Target in Sickle Cell Disease
Identification of novel therapeutic targets has improved diagnostics and treatment of many diseases. Many innovative treatment strategies have been developed based on the newly identified biomarkers and key molecules. Most of the research focused on ways to manipulate signaling pathways by activatin...
Autor principal: | Zennadi, Rahima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839713/ https://www.ncbi.nlm.nih.gov/pubmed/31709379 http://dx.doi.org/10.23937/2469-5696/1410038 |
Ejemplares similares
-
Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease
por: Chauhan, Waseem, et al.
Publicado: (2023) -
MEK Inhibitors, Novel Anti-Adhesive Molecules, Reduce Sickle Red Blood Cell Adhesion In Vitro and In Vivo, and Vasoocclusion In Vivo
por: Zennadi, Rahima
Publicado: (2014) -
The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications
por: Wang, Qinhong, et al.
Publicado: (2021) -
Proteomic analysis of ERK1/2-mediated human sickle red blood cell membrane protein phosphorylation
por: Soderblom, Erik J, et al.
Publicado: (2013) -
Disrupting the vicious cycle created by NOX activation in sickle erythrocytes exposed to hypoxia/reoxygenation prevents adhesion and vasoocclusion
por: MacKinney, Anson, et al.
Publicado: (2019)